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of 900,000 adults. Multiple linear regression analysis of simulation output 
relating LE to levels of BMI was conducted using R. RESULTS: Results were 
obtained for 1855 subjects with mean age 63.6 years, 53% male; 16% current 
smokers; duration of diabetes 9.5 years; HbA1c 7.4%; SBP 135mmHg; total 
cholesterol 195mg/dl and BMI 30.6kg/m2. Using UKPDS mortality risk the 
predicted mean discounted LE was 11.8 years with each unit increase in BMI 
associated with a 0.06 years less life expectancy. Using BMI cause specific 
mortality decreased mean discounted LE to 10.85 years; with each unit increase 
in BMI linearly associated with a 0.2 years reduction in LE. CONCLUSIONS: 
Failure to adequately incorporate the deleterious effect of increasing levels of 
BMI on risk of mortality may substantially distort the health economic 
assessment of type-2 diabetes specific therapies; particularly those associated 
with the avoidance of weight gain or weight loss.  
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OBJECTIVES: To review and systematically synthesize the cost-effectiveness of 
diabetes interventions. METHODS: We conducted a systematic review of cost-
utility analyses (CUAs) related to diabetes published between 1994 and 2012, 
using the Tufts Medical Center Cost-Effectiveness Analysis Registry 
(www.cearegistry.org). We described the study characteristics, such as country, 
type of interventions, perspective, funder, and whether the intervention was 
recommended by the American Diabetes Association (ADA) guidelines. We also 
examined the distribution of the incremental cost-effectiveness ratios (ICERs) 
and used logistic regression to identify factors independently associated with 
favorable ratios (defined as less than the median of all diabetes-related ICERs). 
RESULTS: We identified 167 CUAs from over 20 countries, pertaining to 
interventions for Type 1, Type 2, gestational diabetes mellitus, and diabetes 
complications and comorbidities. Studies conducted in the US and UK accounted 
for 40% and 18% of all CUAs, respectively. Fifty-four percent of diabetes CUAs 
examined pharmaceuticals; 70% focused on tertiary prevention. Most (88%) used 
a health care payer perspective and more than half (52%) were industry-
sponsored. Of 425 published cost-utility ratios, 80% examined an ADA-
recommended intervention (e.g. annual retinopathy screening) relative to a 
comparator. Approximately 71% of interventions examined in diabetes CUAs 
were either cost-saving or below $50,000 per QALY, regardless of whether the 
service was recommended by the ADA. Logistic regression analysis showed that 
CUAs conducted from the US perspective were more likely to report favorable 
ratios than non-US CUAs (OR=2.45; 95% CI=1.12, 5.38). Ratios for diagnostic or 
screening tests were more favorable than other intervention types (OR=3.75; 95% 
CI=1.03, 13.66). CONCLUSIONS: Most interventions examined in diabetes CUAs 
were recommended by the ADA and demonstrated good value for money. 
Further studies are needed to explore the utilization of interventions with 
favorable ratios using the real world data.  
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OBJECTIVES: Hypoglycemia is a major consideration in the management of 
blood glucose in people with type 2 diabetes. NSHE occur more frequently than 
severe episodes and account for the majority of hypoglycemic burden. Recent 
data has quantified the per-event costs of NSHE in terms of productivity loss and 
out-of-pocket expenses. The aim of this study was to model the cost 
implications for NSHE in relation to sulfonylurea or DPP-4 based dual 
combination blood glucose lowering regimens METHODS: Published patient 
source data was used to obtain workplace productivity costs, out-of-pocket (OOP) 
expenses and estimates of the frequency of NSHE. The IMS CORE Diabetes Model 
(CDM) a validated and widely used simulation model was initiated with dual 
therapy patient profiles derived from NHANES and efficacy profiles for 
metformin + sulfonylurea (M+S) versus metformin + DPP-4 (M+D) obtained via a 
mixed treatment comparison. Costs (2010) and benefits are in USD and 
discounted at 3%. RESULTS: In the published patient source data mean weighted 
productivity cost of each NSHE was $34.87 with monthly OOP of $35.56 with 
24.9% of T2DM patients reported NSHE frequency of ‘daily’ to “about 1/week”. 
Assuming a frequency of 1 NSHE per week M+D is associated with an 
incremental annual cost of $212 compared to M+S when including productivity 
and OOP expenses over a 1-year period . Over a lifetime, discounted cost per 
quality adjusted life year gained was $2,419. CONCLUSIONS: Sulfonylurea based 
dual combination therapy is potentially associated with substantially greater 
economic consequences for employers and patients compared with DPP4 based 
dual therapy regimens. Therefore greater consideration should be given to the 
productivity related consequences of hypoglycaemia with respect to dual 
therapy escalation, particularly in people with type 2 diabetes of a working age.  
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OBJECTIVES: Limited data exist on the use of health care resources due to 
hypoglycaemia induced by insulin therapy in diabetes patients. This study 
investigated the frequency of patient-reported non-severe hypoglycaemic events 
(NSHE) in type 1 (T1) and insulin-treated type 2 (T2) diabetes patients and their 
impact on health care resource use in Belgium. METHODS: T1 and T2 diabetes 
patients aged > 15 years were recruited via existing panels to complete four 
questionnaires collecting data at weekly intervals. In addition to demographics, 
data were collected on frequency of NSHE with a 7-day recall period, as well as 
data including impact on patient well-being, work productivity and health care 
resource use. NSHE was defined as an event with symptoms of hypoglycaemia, 
with or without blood glucose measurement (BGM), or low BGM without 
symptoms, which the patient could manage without assistance. Severe 
hypoglycaemic events (SHE), an event needing help from a third party to 
manage, were also reported. RESULTS: Overall, 412 patients (44% T1, 56% T2) 
completed 1148 patient-weeks. Mean NSHE per patient-week were 2.3 in T1 
patients and 0.7 in T2 patients. Following their last NSHE, 64% patients reported 
feeling tired/fatigued, 59% feeling less alert and 37% feeling ill/uncomfortable. 
Over the 7 days following a NSHE, BGM test-strip use increased by 3.4 (mean).  In 
employed patients (38%), 13% of  NHSE were associated with lost work time.  
Following daytime NSHE, 6% of T1 patients and 17% of T2 patients contacted a 
health care professional, plus 8% of T1 and 6% of T2 following a nocturnal NSHE. 
Mean annual frequency of SHE was 0.6. Of the 124 patients reporting a SHE, 17% 
required emergency visits. CONCLUSIONS: NSHE have an economic burden with 
a negative impact on patient well-being. However, the real burden of 
hypoglycaemia may be underestimated since few patients report events to a 
health care professional.  
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OBJECTIVES: Hypoglycaemia is a frequent side effect of insulin treatment for 
patients with diabetes and can impact on quality of life, well-being, work 
productivity and health care resources. This study explored patient-reported 
frequency of non-severe hypoglycaemic events (NSHE) and the impacts of these 
events on patients’ lives and health care resource use in Germany. METHODS: 
Patients over 15 years of age with Type 1 (T1) or insulin-treated Type 2 (T2) (basal 
only T2BOT; basal-bolus T2BB and other regimen T2O) diabetes were recruited in 
Germany via online panels to complete four questionnaires at weekly intervals. 
Data were collected on hypoglycaemia-related resource use and the impact of 
the last hypoglycaemic event on patient well-being and work productivity. NSHE 
was an event with symptoms of hypoglycaemia, with or without blood glucose 
measurement (BGM), or low BGM (≤ 3.1 mmol/l) without symptoms, which the 
patient could manage without assistance. RESULTS: In total, 614 patients (34% 
T1 and 66% T2) participated in the study. Overall self-reported mean NSHE were 
1.0 per patient week (1.6 for T1, 0.6 in T2BOT, 0.6 in T2BB and 0.8 in T2O). 
Following the last NSHE, 64% of patients reported feeling tired/fatigued with 51% 
and 39% feeling less alert and nervous/anxious, respectively. Overall 
employment rate was 53%. A total of 14% of patients reported loss of work time 
due to the last NSHE. Mean increase in BG test-strips use was 3.86 over the 7 
days following each NSHE equating to an estimated additional resource use of 
€2/patient/event (cost/strip €0.5). Following a daytime NSHE 14% of T1 and 23% 
of T2 patients contacted a health care professional (nurse/physician), plus 16% of 
T1 and 13% of T2 patients following night-time events. CONCLUSIONS: NSHE 
have a negative impact on patient well-being and are associated with work time 
loss and increased use of health care resources in Germany.  
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OBJECTIVES: Hypoglycaemia has negative implications for healthcare resources 
and diabetes patients’ quality of life. However, there are limited data available 
on hypoglycaemia in a real-world setting. This study investigated the economic 
and health-related impact of self-reported non-severe hypoglycaemic events 
(NSHE) and severe hypoglycaemic events (SHE) in Spain. METHODS: Patients 
over the age of 15 with type-1 (T1) or insulin-treated type-2 (T2) diabetes were 
recruited via existing panels to complete four questionnaires at weekly intervals. 
Data were collected on frequency of NSHE and SHE, and their impact on patient 
well-being, work productivity and health care resource use. NSHE was defined as 
an event which the patient could manage without assistance and SHE as an 
event needing help from a third party to manage. RESULTS: In total, 630 patients 
completed 2238 patient-weeks. Mean self-reported NSHEs per patient week were 
1.7 in T1 patients and 0.5 in T2 patients. After their last NSHE, 67% of patients 
reported feeling tired/fatigued with 45% feeling less alert and 42% feeling 
ill/uncomfortable. Over the seven days following a NSHE, blood glucose 
measurement test-strip use increased by a mean of 5.3. In employed patients 
(43%), 18% of NSHE were reported to lead to lost work time. A total of 8% of T1 
and 20% of T2 patients contacted a health care professional following a daytime 
NSHE, and 12% (T1) and 20% (T2) following a night-time NSHE. After a SHE, 30% 
of patients required emergency visits. CONCLUSIONS: Hypoglycaemic events are 
a common occurrence in T1 and insulin-treated T2 patients in Spain and present 
an economic burden through increase in health care-resource use and work time 
loss. They also have a negative impact on patient well-being. However, the real 
burden of hypoglycaemia may be underestimated as events are often not 
reported to a health care professional. 
